Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-67856633 + ibrutinib
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**JNJ-67856633 + ibrutinib** is an investigational **oral combination therapy** for hematologic malignancies combining two small-molecule inhibitors: JNJ-67856633 (also known as safimaltib), a potent and selective first-in-class inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1), and ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. JNJ-67856633 targets MALT1 allosterically to inhibit NF-κB signaling, while ibrutinib covalently and irreversibly inhibits BTK in B-cell receptor (BCR) signaling. This combination is being studied for **relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL)** and **chronic lymphocytic leukemia (CLL)**, with the aim of improving outcomes by cotargeting parallel signaling pathways implicated in tumorigenesis and drug resistance[1][3][5][7].
- Other names
- JNJ-67856633 and ibrutinib combinationJNJ67856633 and ibrutinib combinationJNJ 67856633 and ibrutinib combinationsafimaltib and ibrutinib combination
02
Targets
BTK (Bruton tyrosine kinase)ITK (Interleukin 2-inducible T-cell kinase)MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1)
Beyond the preview
Go deeper on JNJ-67856633 + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-67856633 + ibrutinib.